Navigation Links
PharmaDirections is Co-inventor on Second Issued Formulation Patent Entitled “Layered Pharmaceutical Formulations”
Date:5/15/2013

Cary, NC (PRWEB) May 15, 2013

PharmaDirections has added another issued patent to their list of patents where they helped invent new technology for their clients. This one is United States Patent 8,318,788 which has been issued for “Layered Pharmaceutical Formulations”. This was a second patent that was a result of a collaborative formulation development effort between the scientists at Orexigen, PharmaDirections and their sub-contractors.

The technology is for multiple layered pharmaceutical formulations for drug products such as Contrave®, a treatment for obesity. The patent is assigned to Orexigen Therapeutics, Inc. who currently has an NDA for Contrave® under review at the FDA. In the example of an oral, controlled release dosage formulation, the middle layer is inert and dissolves in vivo to leave two separated drug containing layers intact until dissolution begins. This was done to separate potentially interacting layers from one another within the tablet and to allow each pharmaceutical layer to have its own controlled release dissolution profile. The pharmacokinetic modeling and formulation design was done at PharmaDirections.

"Our collaborative effort with Orexigen resulted in multiple accomplishments including this issued patent and the submission of 4 other patent submissions,” said Dr. Richard Soltero, President of PharmaDirections. “This brings us to 21 issued and issued patents for our clients where a PharmaDirections staff member was one of the inventors. We have helped a lot pharmaceutical companies find additional intellectual property by solving problems of bioavailability, stability or off-label competition.”

During the period from 2005 to 2008, PharmaDirections developed and manufactured several products for Orexigen including Contrave® and Empatic™. This relationship was published in Orexigen’s S-1statement issued in 2005 where it noted: “PharmaDirections is our primary drug development consultant and manages subcontractors on our behalf.”

About PharmaDirections:

PharmaDirections is a pharmaceutical project management and consulting group focused on CMC (Chemistry, Manufacturing and Controls), formulation development, preclinical and regulatory affairs. They utilize a mix of technical expertise, software and proprietary tools, such as GastroPlus™, when inventing new intellectual property for clients or developing formulations that solve difficult problems.

Read the full story at http://www.prweb.com/releases/2013/5/prweb10720248.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PharmaDirections Celebrates 10 Years of Success for Their Virtual Biotech and Pharmaceutical Clients
2. Hyperion Wins NDA Approval for UCD Drug Developed With Support from PharmaDirections
3. PharmaDirections Announces Appointment of Dr. Bruce Rehlaender as Principal, Formulation Development
4. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
5. The Second Rarest Job in America: Atlanta Dentist Discusses New Bureau of Labor Statistics that Reveal Low Number of Prosthodontists
6. Dr. Ritchie Shoemaker Pleased to Announce Second Physician Achieves Shoemaker Protocol Certification for Treating Chronic Inflammatory Response Syndrome
7. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
8. Rust Remover That Clears Rust in Seconds Revealed by My Cleaning Products, Company Gives Out Samples of Product to Affirm Effectiveness
9. Genuine Bio Fuel Inc.’s Second Chance Program Proves to Be a Model for Successful Hiring in the Biodiesel Industry
10. Amgen Announces 2013 Second Quarter Dividend
11. Organic-Based Bed Bug Spray Kills Bed Bugs in Seconds, My Cleaning Products Releases Samples of the Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Charlotte, N.C. (PRWEB) , ... October 11, 2017 ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the ... Laboratories ( ASTER Labs ), Inc. has been selected for membership in ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... San Diego-based ... of its corporate rebranding initiative announced today. The bold new look is part ... as the company moves into a significant growth period. , It will also expand ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
Breaking Biology Technology:
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
Breaking Biology News(10 mins):